![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 22, 2013 1:29:17 PM
Late last month Keryx Biopharmaceuticals went from under $4.00 to over $9.00 in two three days. Nothing in the charts would have predicted that. It was because of positive news on one of their drugs in development, Zerenex. Now, the stock did follow a normal momentum pattern of going over its final SP by about 30% before settling down into the $6.00 range. That a chart might have predicted. But that actual move, no chart is going to see that coming.
Likewise, no chart is going to predict the way the market will react to the conference call. That is based on the nature of the new released as well as the expectations of the shareholders.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM